Bon Natural Life Ltd
Bon Natural Life Ltd (BON): 1 pipeline candidate · 2 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.47
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for Bon Natural Life Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.0M
Cash
$6.3M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| clofarabine | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$21K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 15,900 | $21K |
| osaic holdings, inc. | 1 | $1 |
Frequently asked questions
How many drug candidates are in Bon Natural Life Ltd's pipeline?
Bon Natural Life Ltd (BON) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bon Natural Life Ltd's lead drug candidate?
Bon Natural Life Ltd's most advanced tracked candidate is clofarabine (Approved).
What is Bon Natural Life Ltd's market capitalization?
Bon Natural Life Ltd's market capitalization is approximately $13.0M.
Who is the CEO of Bon Natural Life Ltd?
Mr. Yongwei Hu is the chief executive officer of Bon Natural Life Ltd (BON).
Get the full picture on Bon Natural Life Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.